Trastuzumab emtanzin in the treatment of HER2-positive metastatic breast cancer in patients with visceral crisis


DOI: https://dx.doi.org/10.18565/pharmateca.2019.7.58-63

L.Yu. Vladimirova, I.L. Popova, N.A. Abramova, A.E. Storozhakova, N.M. Tikhanovskaya, K.A. Novoselova, A.A. Lyanova, L.A. Ryadinskaya, M.O. Yezhova, M.A. Teplyakov

Rostov Research Institute of Oncology, Rostov-on-Don, Russia

Background. Metastatic breast cancer (mBC) is an incurable disease; modern treatment approaches, however, allow to achieve clinically significant results. Methods. Data on the efficacy and safety of trastuzumab emtansine in the second-line therapy in the treatment of 14 patients with mBC with visceral lesions were analyzed. Results. The overall response to treatment was 71.4% (10 patients), including complete remission in 1 patient, partial remission in 2 (14.3%) patients, stabilization of the process – in 7 (50%), and progression of the process – in 4 (28.6 %) patients. The median of recurrence-free survival was not achieved due to the short follow-up period. Overall recurrence-free survival was 58%, the median overall survival was 9 months. Overall 1-year survival was about 71.4%. The toxic effects of therapy included asthenia, nausea, vomiting, diarrhea, anemia, thrombocytopenia, and leukopenia. Description of the clinical case. The result of the use of the drug in the first-line treatment of HER2-positive breast cancer in a 62-year-old patient with progression during the adjuvant therapy with trastuzumab is presented. Conclusion. The drug has a high efficacy for patients with HER-2 positive mBC with a sufficiently favorable toxicity profile.


For citations: Vladimirova L.Yu., Popova I.L., Abramova N.A., Storozhakova A.E., Tikhanovskaya N.M., Novoselova K.A., Lyanova A.A.,
Ryadinskaya L.A., Yezhova M.O., Teplyakov M.A. Trastuzumab emtanzin in the treatment of HER2-positive metastatic breast cancer in patients with visceral crisis. Farmateka. 2019;26(7):58–63. (in Russian). DOI: https://dx.doi.org/10.18565/pharmateca.2019.7.58-63 


About the Autors


Corresponding author: Liubov Yu. Vladimirova, MD Professor, Head of the Division of Medicinal Treatment of Tumors, Rostov Research Institute of Oncology, Rostov-on-Don, Russia; e-mail: vlu@aaanet.ru
Address: 63, 14th Line Street, Rostov-on-Don 344037, Russian Federation


Similar Articles


Бионика Медиа